Riesgo-beneficio de los Inhibidores de la bomba de protones

BIBLIOGRAFÍA

1. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors - What the practising physician needs to know. Drugs 2003;63:2739- 54.

2. García del Pozo J. Estudio de utilización de antiulcerosos en España (2000-2008). Inf Ter Sist Nac Salud 2009;33:49-54.

3. Ministerio de Sanidad. Subgrupos ATC y Principios activos de mayor consumo en el Sistema Nacional de Salud en 2010. Inf Ter Sist Nac Salud 2010;35:124-8.

4. Ponce J, Esplugues JV. Rationalizing the use of PPIs: An unresolved matter. Rev Esp Enferm Dig 2013;105:121-4. DOI: 10.4321/S1130- 01082013000300001

5. Simo Minana J. Use of prescription drugs in Spain and Europe. Aten Primaria. 2012;44:335-47.

6. Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005;21:1203-9. DOI: 10.1111/j.1365-2036.2005.02454.x

7. Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010;49:2561-8. DOI: 10.2169/internalmedicine.49.4064

8. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001;23:116-7.

9. de Burgos Lunar C, Novo del Castillo S, Llorente Diaz E, et al. Study of prescription-indication of proton pump inhibitors. Rev Clin Esp 2006;206:266-70.

10. Martin-Echevarria E, Pereira Julia A, Torralba M, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig 2008;100:76-81.

11. Batuwitage BT, Kingham JGC, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-8. DOI: 10.1136/pgmj.2006.051151 220 C. DE LA COBA ET AL. Rev Esp Enferm Dig (Madrid) Rev Esp Enferm Dig 2016; 108 (4): 207-224

12. Ahrens D, Chenot J-F, Behrens G, et al. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 2010;66:1265-71. DOI: 10.1007/s00228-010-0871-9

13. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Brit J Clin Pharmacol 2010;69:543-52. DOI: 10.1111/j.1365- 2125.2010.03628.x

14. Villamanan E, Ruano M, Lara C, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig 2015;107:652-8.

15. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010;5:288-97.

16. Ahrens D, Behrens G, Himmel W, et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract 2012; 66:767-73. DOI: 10.1111/j.1742-1241.2012.02973.x

17. Ponce Romero M, Berenguer Lapuerta J. Current indications for proton pump inhibitors. Rev Clin Esp 2003;203:136-8.

18. Grupo de trabajo Sector Zaragoza I Salud. Empleo de los inhibidores de la bomba de protones en la prevención de gastropatías secundarias a fármacos. Guía de Práctica Clínica. Zaragoza: Guía Salud; 2012.

19. Product Characteristics. Spanish Agency of Medicines and Medical Devices.

20. Arroyo Villarino M, Lanas Arbeloa A. Gastroenteropatía por AINE. En: Ponce García J, editor. Asociación Española de Gastroenterología. Tratamiento de las enfermedades gastroenterológicas. Barcelona: Elsevier; 2011. p. 123-31.

21. Pérez Gisbert J, Martín Argila C. Úlcera péptica e infección por Helicobacter pylori. En: Ponce García J, editor. Asociación Española de Gastroenterología. Tratamiento de las enfermedades gastroenterológicas. Barcelona: Elsevier; 2011. p. 109-21.

22. Sung JJY, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding - a randomized trial. Ann Intern Med 2009;150:455-64. DOI: 10.7326/0003-4819-150-7- 200904070-00105

23. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers - a systematic review and meta-analysis. JAMA Intern Med 2014;174:1755-62. DOI: 10.1001/jamainternmed.2014.4056

24. Yen H-H, Yang C-W, Su W-W, et al. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012;12:66. DOI: 10.1186/1471-230X-12-66

25. Pérez-Gisbert J, Calvet X, Ferrandiz J, et al. Clinical practice guideline on the management of patients with dyspepsia. Update 2012. Gastroenterol Hepatol 2012;35:725.e1-38.

26. Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:1066-78.

27. Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:13-22.e1. DOI: 10.1016/j.cgh.2015.07.041

28. Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 2015; (online first): pii: gutjnl-2015-310991. Accesible en: http://www.ncbi.nlm.nih. gov/pubmed/26685124 DOI: 10.1136/gutjnl-2015-310991

29. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut 2006;55:1056-7. DOI: 10.1136/gut.2006.094912

30. Stabler SP. Vitamin B-12 Deficiency. N Engl J Med 2013;368:149-60.

31. Jung SB, Nagaraja V, Kapur A, et al. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J 2015;45:409-16.

32. Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B-12 deficiency. JAMA 2013;310:2435-42. DOI: 10.1001/jama.2013.280490

33. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc 2008;9:162-7. DOI: 10.1016/j.jamda.2007.10.004

34. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B-12 deficiency in older adults. J Clin Epidemiol 2004;57:422-8. DOI: 10.1016/j. jclinepi.2003.08.015

35. Force RW, Meeker AD, Cady PS, et al. Increased vitamin B-12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003;37:490-3.

36. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994;120:211-5. DOI: 10.7326/0003-4819-120-3-199402010-00006

37. Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol 2001;54:531-4. DOI: 10.1016/S0895-4356(00)00340-1

38. Koop H. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406. DOI: 10.1111/j.1365-2036.1992.tb00553.x

39. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B-12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-30. DOI: 10.1016/S0002-9343(98)00087-4

40. Rozgony NR, Fang C, Kuczmarski MF, et al. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 2010;29:87-99. DOI: 10.1080/01639360903574734

41. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-92. DOI: 10.1097/00004836-199206000-00005

42. Schenk BE, Festen HPM, Kuipers EJ, et al. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996;10:541-5. DOI: 10.1046/j.1365-2036.1996.27169000.x

43. Den Elzen WPJ, Groeneveld Y, De Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008;27:491-7. DOI: 10.1111/j.1365- 2036.2008.03601.x

44. ter Heide H, Hendriks HJE, Heijmans H, et al. Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B-12 deficiency? J Pediatr Gastroenterol Nutr 2001;33:342-5. DOI: 10.1097/00005176-200109000-00023

45. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: A retrospective review of safety. Dig Dis Sci 2008;53:385-93. DOI: 10.1007/s10620-007-9880-7

46. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-21. DOI: 10.1111/j.1365-2036.2008.03658.x

47. Long AN, Atwell CL, Yoo W, et al. Vitamin B-12 deficiency associated with concomitant metformin and proton pump inhibitor use. Diabetes Care 2012;35:E84-E. DOI: 10.2337/dc12-0980

48. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015;41:1162-74. DOI: 10.1111/apt.13194

49. Bellou A, AimoneGastin I, DeKorwin JD, et al. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J Intern Med 1996;240:161-4. DOI: 10.1046/j.1365- 2796.1996.20846000.x

50. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015;265:419-28. DOI: 10.1007/s00406-014-0554-0

51. Rajabally YA, Jacob S. Neuropathy associated with lansoprazole treatment. Muscle Nerve 2005;31:124-5. DOI: 10.1002/mus.20155

52. Sellapah S. An unusual side effect of ome Vol. 108, N.º 4, 2016 EFECTOS ADVERSOS DE LOS INHIBIDORES DE LA BOMBA DE PROTONES: REVISIÓN DE EVIDENCIAS 221 Y POSICIONAMIENTO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA Rev Esp Enferm Dig 2016; 108 (4): 207-224 kidney disease. J Am Geriatr Soc 2012;60:392-3. DOI: 10.1111/j.1532- 5415.2011.03808.x

55. Gau J-T, Yang Y-X, Chen R, et al. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012;21:553-9. DOI: 10.1002/pds.3224 56. Sharara AI, Chalhoub JM, Hammoud N, et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol 2016;14:317-21. DOI: 10.1016/j.cgh.2015.10.012

57. Chen J, Yuan YC, Leontiadis GI, et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012;46:93-114. DOI: 10.1097/MCG.0b013e3182333820

58. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-6. DOI: 10.1056/NEJMc066308

59. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Riesgo de hipomagnesemia asociado a los medicamentos inhibidores de la bomba de protones (IBP). Ref. MUH (FV), 27/2011. Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/docs/NI-MUH_27-2011.pdf. [visitado 23/12/15]

60. FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Washington, DC: US. Food and Drug Administration; 2011. Accesible en: http://www.fda.gov/Drugs/DrugSafety/ucm213206.htm.

61. Administration TG. Risk of hypomagnesaemia with proton pump inhibitors. Medicines Safety Update Vol 2, Number 3. Australian Prescriber 2011;34:81. Accesible en: https://www.tga.gov.au/publicationissue/medicines-safety-update-vol-2-no-3-june-2011

62. Park CH, Kim EH, Roh YH, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis. PLoS One 2014;9:e112558. DOI: 10.1371/ journal.pone.0112558

63. Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013;47:773-80. DOI: 10.1345/aph.1R556

64. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015;37:1237-41. DOI: 10.3109/0886022X.2015.1057800

65. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H-2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. DOI: 10.1007/ s00223-006-0021-7

66. Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-53. DOI: 10.1001/jama.296.24.2947

67. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008;179:319-26. DOI: 10.1503/cmaj.071330

68. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9. DOI: 10.1592/phco.28.8.951

69. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9. DOI: 10.1007/s00223-008-9170-1

70. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-9. DOI: 10.1007/s00223-008-9188-4

71. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101. DOI: 10.1053/j. gastro.2010.03.055

72. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women results from the women’s health initiative. Arch Intern Med 2010;170:765-71. DOI: 10.1001/archinternmed.2010.94

73. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based casecontrol study. Osteoporos Int 2011;22:903-10. DOI: 10.1007/s00198- 010-1337-8

74. Reyes C, Formiga F, Coderch M, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 2013;52:557-61. DOI: 10.1016/j.bone.2012.09.028

75. Cea Soriano L, Ruigomez A, Johansson S, et al. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 2014;34:570-81. DOI: 10.1002/ phar.1410

76. Ding J, Heller DA, Ahern FM, et al. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int 2014;94:597-607. DOI: 10.1007/s00223-014-9855-6

77. van der Hoorn MMC, Tett SE, de Vries OJ, et al. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 2015;81:675-82. DOI: 10.1016/j.bone.2015.08.024

78. Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a populationbased study. Osteoporos Int 2015; 26: 2501-7. DOI: 10.1007/s00198- 015-3168-0

79. Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Br Med J 2012;344. DOI: 10.1136/bmj.e372

80. Adams AL, Black MH, Zhang JL, et al. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol 2014;24:286-90.

81. Lewis JR, Barre D, Zhu K, et al. Long-Term proton pump inhibitor therapy and falls and fractures in elderly women: A prospective cohort study. J Bone Miner Res 2014;29:2489-97. DOI: 10.1002/jbmr.2279

82. Moberg LME, Nilsson PM, Samsioe G, et al. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 2014;78:310-5. DOI: 10.1016/j.maturitas.2014.05.019

83. Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19:1131-6. DOI: 10.1002/ pds.2026

84. Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 2013;24:1161-8.

85. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998- 1004. DOI: 10.1001/archinternmed.2011.20

86. de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009;20:1989-98. DOI: 10.1007/ s00198-009-0891-4

87. Itoh S, Sekino Y, Shinomiya K-i, et al. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 2013;31:206-11. DOI: 10.1007/s00774-012-0406-9

88. Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013;48:1016-22. DOI: 10.1007/s00535-012- 0722-9

89. Eom C-S, Park SM, Myung S-K, et al. Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies. Ann Fam Med 2011;9:257-67. DOI: 10.1370/afm.1243

90. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209-18. DOI: 10.1038/ajg.2011.113

91. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: A meta-analysis of 11 international studies. Am J Med 2011;124:519-26.

92. Yang S-D, Chen Q, Wei H-K, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med 2015; 8:4899-910.

93. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 2015. Accesible en: http://www.ncbi.nlm.nih.gov/pubmed/26462494

94. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998;12:43-53. DOI: 10.2165/00002512- 199812010-00005 222 C. DE LA COBA ET AL. Rev Esp Enferm Dig (Madrid) Rev Esp Enferm Dig 2016; 108 (4): 207-224